GlassScriptPhysician profile
Paul David Francis
NPI 1154088482
$4,645.50
in general payments reported to CMS, 2019-2025
18 companies · $1,588 in 2025
The $1,588 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $174 · 2022: $616 · 2023: $1,074 · 2024: $1,193 · 2025: $1,588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,840 · Education: $15.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,840.48 |
| Education | $15.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $605.92 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $516.00 | 2024-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $485.20 | 2021-2025 | |
| Alkermes, INC. | $435.42 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Lundbeck LLC | $392.72 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Indivior INC. | $391.03 | 2022-2025 | Sublocade, Perseris |
| Otsuka America Pharmaceutical, INC. | $389.98 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $389.77 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $373.83 | 2022-2025 | Invega Sustenna, Spravato, Invega |
| Neurocrine Biosciences, INC. | $214.68 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $143.60 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $94.55 | 2025 | Cobenfy |
| Corium, LLC | $71.56 | 2022-2024 | Azstarys |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $46.66 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $39.51 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $23.80 | 2025 | Jornay Pm |
| Tris Pharma INC | $16.23 | 2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $15.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Francis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.